Invest Like Seth Klarman: Paypal Holdings Inc., Keryx Biopharmaceuticals, Micron Technology, Inc.

Many call Seth Klarman a modern day investing legend due to his expertise in value investing. However in the third quarter, Klarman’s hedge fund, Baupost Group, had a rough quarter, losing 22.42% of its value compared to the S&P 500 which lost about 7% in the same time period. Here are some of Klarman’s holdings that raise some eyebrows: Paypal Holdings Inc (Nasdaq: PYPL), Keryx Biopharmaceuticals (Nasdaq: KERX), and Micron Technology, Inc. (Nasdaq: MU).

Klarman 1

Klarman 2

Paypal Holdings Inc

Paypal, the online payment system, was established in the third quarter as a standalone company independent of eBay. Klarman did not waste any time adding the company to his holdings as it is now makes up more than 5% of his portfolio with his shares valued at $338 million.

The stock took off quickly, though ultimately fell more than 15% in the third quarter. However since the close of the third quarter, Paypal shares are up more than 4%. Most analysts are bullish on the new company due its loyal user base and strong name recognition; though many are giving it time to establish itself in the e-commerce market and prove itself in the face of competitors, such as Venmo.

Most analysts polled by TipRanks in the last 3 months have the same bullish sentiment on the stock as Klarman, with 14 recommending to Buy shares of Paypal. On the other hand, 2 analysts are bearish and 3 remain neutral. The average 12-month price target between these 19 analysts is $42.82, marking a 32% potential upside from current levels.

Keryx Biopharmaceuticals

Keryx, a small-cap biotechnology company that focuses on renal diseases, comprises more than 1.50% of Klarman’s holdings with nearly 26 million shares valued at over $90 million. The company has had a tough year due to Auryxia sales; the company’s lead product to control serum phosphorous levels in patients with chronic kidney disease (CKD) on dialysis. Analysts blamed disappointing Auryxia figures on challenges in rolling out the drug, but most agree the growing pains will stop once Keryx expands its sales force for the drug.

1 2
View single page >> |

Note: All analyst photos and statistics in this article are measured over a three-month horizon. Links to analysts ...

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
Craig Newman 4 years ago Member's comment

Invest like Seth Klarman by shorting these stocks. It's the only way his investment is making money.